Literature DB >> 6988003

Comparison of labetalol and propranolol in hypertension.

D P Nicholls, M H Husaini, C J Bulpitt, M D Stephens, A G Butler.   

Abstract

1 Labetalol has been compared with propranolol in a double-blind, double-dummy study of 24 patients with mild or moderate essential hypertension. 2 Two patients were unable to tolerate propranolol and five labetalol, because of symptom side effects; this difference was not significant (P greater than 0.1). 3 On a self-administered questionnaire, labetalol was associated with a greater number of side effects per patient than propranolol, but no individual side effect was significantly more common with either drug. 4 There was no difference in the number of spontaneously reported side effects between the two drugs. 5 Both drugs impaired pulmonary function, but propranolol caused a greater reduction than labetalol after 8 weeks of treatment. 6 We conclude that labetalol and propranolol are similarly effective and acceptable to the patient.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6988003      PMCID: PMC1429887          DOI: 10.1111/j.1365-2125.1980.tb04832.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  Comparison of intravenous AH 5158 (ibidomide) and propranolol in asthma.

Authors:  C Skinner; J Gaddie; K N Palmer
Journal:  Br Med J       Date:  1975-04-12

2.  A symptom questionnaire for hypertensive patients.

Authors:  C J Bulpitt; C T Dollery; S Carne
Journal:  J Chronic Dis       Date:  1974-08

3.  Alpha and beta adrenergic blockade in hypertension.

Authors:  L J Beilin; B E Juel-Jensen
Journal:  Lancet       Date:  1972-05-06       Impact factor: 79.321

4.  A random-zero sphygmomanometer.

Authors:  B M Wright; C F Dore
Journal:  Lancet       Date:  1970-02-14       Impact factor: 79.321

5.  Alpha- and beta-adrenergic receptor blockade in the treatment of hypertension.

Authors:  P A Majid; M K Meeran; M E Benaim; B Sharma; S H Taylor
Journal:  Br Heart J       Date:  1974-06

6.  Beta adrenergic blockade in hypertension. Practical and theoretical implications of long-term hemodynamic variations.

Authors:  R C Tarazi; H P Dustan
Journal:  Am J Cardiol       Date:  1972-05       Impact factor: 2.778

7.  Combined alpha- and beta-adrenoceptor blockade with labetalol in hypertension.

Authors:  M H Frick; P Pörsti
Journal:  Br Med J       Date:  1976-05-01

Review 8.  A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.

Authors:  R T Brittain; G P Levy
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

9.  Comparative anti-hypertensive effects of labetalol and the combination of oxprenolol and phentolamine.

Authors:  B F Johnson; J LaBrooy; A D Munro-Faure
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

10.  Side effects of hypotensive agents evaluated by a self-administered questionnaire.

Authors:  C J Bulpitt; C T Dollery
Journal:  Br Med J       Date:  1973-09-01
View more
  5 in total

Review 1.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

2.  Cold sensitivity in essential hypertension: the effect of beta- and combined alpha- and beta-blockade.

Authors:  E D Cooke; S A Bowcock; A T Smith
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 3.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

4.  Propranolol vs metoprolol vs labetalol: a comparative study in essential hypertension.

Authors:  M M Kubik; J H Coote
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 5.  Eliciting adverse effects data from participants in clinical trials.

Authors:  Elizabeth N Allen; Clare Ir Chandler; Nyaradzo Mandimika; Cordelia Leisegang; Karen Barnes
Journal:  Cochrane Database Syst Rev       Date:  2018-01-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.